Loading...
OTCM
CNVVY
Market cap6.60bUSD
Apr 11, Last price  
12.87USD
1D
1.59%
1Q
16.48%
IPO
5.93%
Name

ConvaTec Group PLC

Chart & Performance

D1W1MN
P/E
201.39
P/S
12.25
EPS
0.06
Div Yield, %
1.96%
Shrs. gr., 5y
0.95%
Rev. gr., 5y
3.18%
Revenues
2.29b
+6.85%
1,700,700,0001,733,900,0001,650,400,0001,688,300,0001,764,600,0001,832,100,0001,827,200,0001,894,300,0002,038,300,0002,072,500,0002,142,400,0002,289,200,000
Net income
191m
+46.20%
-173,700,000-286,500,000-93,400,000-202,800,000158,400,000221,600,0009,800,000112,500,000117,600,00062,900,000130,300,000190,500,000
CFO
396m
+7.84%
229,100,000147,300,000100,300,00074,900,000306,600,000352,000,000401,800,000399,500,000305,900,000281,700,000367,400,000396,200,000
Dividend
Aug 23, 20240.073 USD/sh
Earnings
May 16, 2025

Profile

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
URL
https://www.convatecgroup.com/
IPO date
Oct 26, 2016
Employees
10,000
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,289,200
6.85%
2,142,400
3.37%
2,072,500
1.68%
Cost of revenue
1,957,500
1,859,500
1,817,800
Unusual Expense (Income)
NOPBT
331,700
282,900
254,700
NOPBT Margin
14.49%
13.20%
12.29%
Operating Taxes
56,000
37,100
19,000
Tax Rate
16.88%
13.11%
7.46%
NOPAT
275,700
245,800
235,700
Net income
190,500
46.20%
130,300
107.15%
62,900
-46.51%
Dividends
(130,200)
(110,700)
(88,100)
Dividend yield
2.86%
2.21%
1.86%
Proceeds from repurchase of equity
(10,900)
BB yield
0.24%
Debt
Debt current
22,000
20,700
20,300
Long-term debt
1,258,400
1,377,200
1,300,500
Deferred revenue
1,129,000
Other long-term liabilities
51,500
192,900
(1,212,200)
Net debt
1,215,700
1,276,700
1,144,100
Cash flow
Cash from operating activities
396,200
367,400
281,700
CAPEX
(122,100)
(129,200)
(144,200)
Cash from investing activities
(160,800)
(285,700)
(348,300)
Cash from financing activities
(263,800)
(124,000)
(237,100)
FCF
266,900
95,000
216,200
Balance
Cash
64,700
98,300
145,800
Long term investments
22,900
30,900
Excess cash
14,080
73,075
Stockholders' equity
(576,900)
(637,200)
1,445,500
Invested Capital
3,518,900
3,835,200
2,863,425
ROIC
7.50%
7.34%
10.67%
ROCE
10.97%
8.85%
8.43%
EV
Common stock shares outstanding
2,056,797
2,052,589
2,040,247
Price
2.21
-9.42%
2.44
4.99%
2.33
20.42%
Market cap
4,549,635
-9.23%
5,012,423
5.62%
4,745,616
21.25%
EV
5,765,335
6,289,123
5,889,716
EBITDA
552,500
497,700
450,800
EV/EBITDA
10.43
12.64
13.07
Interest
73,500
73,300
64,700
Interest/NOPBT
22.16%
25.91%
25.40%